Dexlansoprazole prevents pulmonary artery hypertension by inhibiting pulmonary artery smooth muscle cell to fibroblast transition

CONCLUSIONS: Dexlansoprazole can prevent PAH through promoting cGMP generation and inhibiting pulmonary vascular remodeling through restraining PASMCs' proliferation, migration, and phenotypic transition to fibroblast-like cells. Consequently, PAH might be a new indication for dexlansoprazole.PMID:36105026 | PMC:PMC9452313

Source: American Journal of Translational Research - September 15, 2022 Category: Research Authors: Qian Jiao Fangdi Zou Shiliang Li Jiawen Wang Yunping Xiao Zhihua Guan Liang Dong Jinwei Tian Shengqing Li Rui Wang Jian Zhang Honglin Li Source Type: research